[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Australia Generics Market Summary, Competitive Analysis and Forecast to 2027

July 2023 | 45 pages | ID: AEEE86D83AC3EN
MarketLine

US$ 350.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Australia Generics Market Summary, Competitive Analysis and Forecast to 2027

Summary

Generics in Australia industry profile provides top-line qualitative and quantitative summary information including: market size (value 2017-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights
  • For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. The market value is evaluated at ex-factory prices.
  • The Australian generics market had total revenues of $2.0 billion in 2022, representing a compound annual growth rate (CAGR) of 6.4% between 2017 and 2022.
  • Market consumption volume increased with a CAGR of 5.3% between 2017 and 2022, to reach a total of 75.2% in 2022.
  • Australia has in place the Generic Medicines Working Group (GMWG) which is responsible for policy development and discussion aimed at promoting the use of generic medications in Australia. Such efforts are boosting the country’s generics market.
Scope
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Australia
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Australia
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Australia generics market with five year forecasts
Reasons to Buy
  • What was the size of the Australia generics market by value in 2022?
  • What will be the size of the Australia generics market in 2027?
  • What factors are affecting the strength of competition in the Australia generics market?
  • How has the market performed over the last five years?
  • How large is Australia’s generics market in relation to its regional counterparts?
1 EXECUTIVE SUMMARY

1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive landscape

2 MARKET OVERVIEW

2.1. Market definition
2.2. Market analysis

3 MARKET DATA

3.1. Market value
3.2. Market volume

4 MARKET SEGMENTATION

4.1. Geography segmentation

5 MARKET OUTLOOK

5.1. Market value forecast
5.2. Market volume forecast

6 FIVE FORCES ANALYSIS

6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry

7 COMPETITIVE LANDSCAPE

7.1. Who are the leading players?
7.2. What are the strengths of the leading players?
7.3. Have there been any recent developments in the market?

8 COMPANY PROFILES

8.1. Teva Pharmaceutical Industries Limited
8.2. Viatris Inc.
8.3. Lupin Ltd
8.4. Aspen Pharmacare Holdings Ltd

9 MACROECONOMIC INDICATORS

9.1. Country data

10 APPENDIX

10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine

LIST OF TABLES

Table 1: Australia generics market value: $ million, 2017-22
Table 2: Australia generics market volume: %, 2017-22
Table 3: Australia generics market geography segmentation: $ million, 2022
Table 4: Australia generics market value forecast: $ million, 2022-27
Table 5: Australia generics market volume forecast: %, 2022-27
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Viatris Inc.: key facts
Table 10: Viatris Inc.: Annual Financial Ratios
Table 11: Viatris Inc.: Key Employees
Table 12: Viatris Inc.: Key Employees Continued
Table 13: Lupin Ltd: key facts
Table 14: Lupin Ltd: Annual Financial Ratios
Table 15: Lupin Ltd: Key Employees
Table 16: Aspen Pharmacare Holdings Ltd: key facts
Table 17: Aspen Pharmacare Holdings Ltd: Annual Financial Ratios
Table 18: Aspen Pharmacare Holdings Ltd: Key Employees
Table 19: Australia size of population (million), 2018-22
Table 20: Australia gdp (constant 2005 prices, $ billion), 2018-22
Table 21: Australia gdp (current prices, $ billion), 2018-22
Table 22: Australia inflation, 2018-22
Table 23: Australia consumer price index (absolute), 2018-22
Table 24: Australia exchange rate, 2018-22

LIST OF FIGURES

Figure 1: Australia generics market value: $ million, 2017-22
Figure 2: Australia generics market volume: %, 2017-22
Figure 3: Australia generics market geography segmentation: % share, by value, 2022
Figure 4: Australia generics market value forecast: $ million, 2022-27
Figure 5: Australia generics market volume forecast: %, 2022-27
Figure 6: Forces driving competition in the generics market in Australia, 2022
Figure 7: Drivers of buyer power in the generics market in Australia, 2022
Figure 8: Drivers of supplier power in the generics market in Australia, 2022
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Australia, 2022
Figure 10: Factors influencing the threat of substitutes in the generics market in Australia, 2022
Figure 11: Drivers of degree of rivalry in the generics market in Australia, 2022


More Publications